As expected both, HT-29 as well as DLD-1 CRC cell lines exhibiting an activating BRAF or KRAS mutation, respectively, did not respond to the treatment with the EGFR inhibitor under 2D and lrECM 3D (Figure 6F and G). The gene discussed is BRAF; the disease is colorectal carcinoma.